Studientyp
Systemtherapie 1. Linie (metastasierte Erkrankung / Hämatologie)
Beschreibung für Experten
Phase I trial to assess the cardiac safety of treosulfan-based conditioning therapy in subjects with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation
Beschreibung
Phase I trial to assess the cardiac safety of treosulfan-based conditioning therapy in subjects with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation
JSON Daten
{
"short_title": "MC-FludT.18 QT",
"data_mode": "910",
"data_mode_number": "000000020",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": " 2021-005433-16",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": " Phase I trial to assess the cardiac safety of treosulfan-based conditioning therapy in subjects with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation",
"description_laie_en": "Phase-I-Studie zur Beurteilung der kardialen Sicherheit einer Konditionierungstherapie auf Treosulfan-Basis bei Patienten mit AML oder MDS, die sich einer allogenen h\u00e4matopoetischen Stammzelltransplantation unterziehen",
"description_expert_de": " Phase I trial to assess the cardiac safety of treosulfan-based conditioning therapy in subjects with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation",
"description_expert_en": "Phase-I-Studie zur Beurteilung der kardialen Sicherheit einer Konditionierungstherapie auf Treosulfan-Basis bei Patienten mit AML oder MDS, die sich einer allogenen h\u00e4matopoetischen Stammzelltransplantation unterziehen",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 30
}
